Compounded Tirzepatide
Tirzepatide prepared by a compounding pharmacy rather than Eli Lilly. It is not FDA-approved, and since the shortage ended it is limited to patient-specific 503A prescriptions.
Compounded tirzepatide became widely marketed during the Mounjaro/Zepbound shortage period. Its legal availability hinges on whether the FDA lists tirzepatide as in shortage; once removed, traditional compounding under the 503A pathway is significantly restricted. Patients should confirm their compounded preparation comes from a state-licensed pharmacy and ask about sterility, potency testing, and excipients.